Welcome to Conversations on Colorectal Cancer on ReachMD, sponsored by Lilly.
On today’s program, we’ll hear from Dr. Putao Cen, Associate Professor of Medical Oncology at The University of Texas Health Science Center McGovern Medical School. Dr. Cen compares anti-EGFR therapies for left verses right-sided colorectal tumors. Here she is now.
So on the EGFR inhibitor, the left side colon achieved higher response rate and longer overall survival from the EGFR inhibitor in RAS wild-type colorectal cancer compared to right side colon. For example, in CRYSTAL study compared FOLFIRI with cetuximab versus FOLFIRI alone in RAS wild-type subpopulations of the clinical trial, left side colon cancer has a median survival of 28 months versus 21 months in right side colon cancer. So the left side has a better – 7 months better median survival compared to right side. On the FIRE-3 study, compared cetuximab with the FOLFIRI versus bevacizumab with FOLFIRI, the left side colon cancer overall survival was 33 months, the right side colon cancer was 28 months in RAS wild-type subpopulations. So the overall survival is 10 months better in left side colon cancer. In CALGB/SWOG 80405 study compared FOLFIRI backbone the dealer choice by the oncologist combined with cetuximab versus FOLFOX/FOLFIRI backbone with bevacizumab. The left side colon cancer, the median survival is 39.3 months, almost 40 months overall survival compared to right side colon cancer at 32 months overall survival. So the left side has a 6.7 months better overall survival if we give the cetuximab first-line in the left side colon cancer.
That was Dr. Putao Cen reviewing anti-EGFR therapies for colorectal tumors and the latest survival trends in clinical trials. To revisit any part of this discussion and to access other episodes in this series, visit ReachMD.com/mCRC, where you can Be Part of the Knowledge.